Acute myeloid leukemia (AML) has a poor prognosis after development of resistance to chemotherapy , chimeric antigen receptor (CAR) T immunotherapy has been successful in treating B cell-lineage mali gnancies by targeting CD19 , however, CAR T immunotherapy for AML is hindered by the challenge of toxic side effect including those that are on-target/off-tumor.The conventional CD13 CAR redir- ected by Nb157 eliminated AML in vitro and in vivo, but also damaged the normal hematopoietic stem cell (HSC) in a humanized immunol. system (HIS) mouse model.Herein we used sCAR T cells targeting CD13 to induce complete remission in AML, following the adminis- tration of the Nb157-switch targeting CD13, in both an AML cell line and patient-derived AML in vitro and in vivo.It is worth noting that CD13 is also expressed in some normal tissues besides hematopoietic cells, such as liver or kidney, and potential off-tumor toxicity for these tissues remains further evaluated. Toge- ther, these results demonstrate that the use of Nb switch in combination with sCAR can eradicate AML, while partially preserving HSC.